B. Riley Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

B. Riley Wealth Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,473	Closed	-$300K	–	1036
2025 Q3	$300K	Buy	2,473 +2	+0.1%	+$225	0.01%	729
2025 Q2	$258K	Sell	2,471 -618	-20%	-$65.4K	0.01%	776
2025 Q1	$360K	Buy	+3,089	New	+$352K	0.01%	888
2023 Q3	–	Sell	-3,347	Closed	-$241K	–	1474
2023 Q2	$241K	Buy	+3,347	New	+$247K	0.01%	1248
2023 Q1	–	Sell	-3,361	Closed	-$259K	–	1527
2022 Q4	$259K	Buy	+3,361	New	+$201K	0.01%	1111
2021 Q3	–	Sell	-4,147	Closed	-$280K	–	1415
2021 Q2	$280K	Buy	+4,147	New	+$249K	0.01%	1056
2020 Q3	–	Sell	-6,450	Closed	-$531K	–	948
2020 Q2	$531K	Buy	+6,450	New	+$496K	0.04%	441

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

B. Riley Wealth Advisors's AXSM Position: Q4 2025 in Review

B. Riley Wealth Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 2,473 shares — an estimated $300K sold.

B. Riley Wealth Advisors first reported a position in AXSM in Q2 2020 and held it in 7 quarters. The position peaked at $531K in Q2 2020. 399 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

B. Riley Wealth Advisors reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
B. Riley Wealth Advisors sold 2,473 Axsome Therapeutics shares in Q4 2025, an estimated $300K.
B. Riley Wealth Advisors first reported a position in Axsome Therapeutics in Q2 2020 and held it in 7 quarters.
B. Riley Wealth Advisors's Axsome Therapeutics position peaked at $531K in Q2 2020.
399 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.